Anavex Life Sciences
Market Cap
US$967.3m
Last Updated
2021/03/03 23:21 UTC
Data Sources
Company Financials +
Executive Summary
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with moderate growth potential.
Share Price & News
How has Anavex Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVXL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: AVXL's weekly volatility has increased from 15% to 21% over the past year.
Market Performance
7 Day Return
8.7%
AVXL
-5.9%
US Biotechs
-3.4%
US Market
1 Year Return
216.0%
AVXL
21.7%
US Biotechs
29.4%
US Market
Return vs Industry: AVXL exceeded the US Biotechs industry which returned 21.7% over the past year.
Return vs Market: AVXL exceeded the US Market which returned 29.4% over the past year.
Shareholder returns
| AVXL | Industry | Market | |
|---|---|---|---|
| 7 Day | 8.7% | -5.9% | -3.4% |
| 30 Day | 105.7% | -7.0% | 0.6% |
| 90 Day | 170.8% | 0.8% | 6.3% |
| 1 Year | 216.0%216.0% | 23.5%21.7% | 32.2%29.4% |
| 3 Year | 364.7%364.7% | 14.4%8.7% | 51.3%41.7% |
| 5 Year | 160.3%160.3% | 51.4%40.3% | 119.6%95.2% |
Long-Term Price Volatility Vs. Market
How volatile is Anavex Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation5 months ago | Simply Wall St
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth8 months ago | Simply Wall St
How Many Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Do Institutions Own?Valuation
Is Anavex Life Sciences undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVXL ($13.43) is trading below our estimate of fair value ($49.98)
Significantly Below Fair Value: AVXL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVXL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AVXL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVXL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVXL is overvalued based on its PB Ratio (19.4x) compared to the US Biotechs industry average (4.1x).
Next Steps
Future Growth
How is Anavex Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
75.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVXL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AVXL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AVXL's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if AVXL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AVXL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVXL's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Anavex Life Sciences performed over the past 5 years?
-16.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVXL is currently unprofitable.
Growing Profit Margin: AVXL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVXL is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare AVXL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVXL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: AVXL has a negative Return on Equity (-59.49%), as it is currently unprofitable.
Next Steps
Financial Health
How is Anavex Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: AVXL's short term assets ($54.3M) exceed its short term liabilities ($8.0M).
Long Term Liabilities: AVXL has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AVXL is debt free.
Reducing Debt: AVXL has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVXL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AVXL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 27.2% each year.
Next Steps
Dividend
What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVXL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVXL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVXL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.4yrs
Average management tenure
CEO
Chris Missling (54 yo)
7.67yrs
Tenure
US$1,841,048
Compensation
Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and had been its Chief Financial O...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD1.84M) is about average for companies of similar size in the US market ($USD2.20M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.67yrs | US$1.84m | 1.47% $ 14.2m | |
| Principal Financial Officer & Treasurer | 5.42yrs | US$295.22k | 0.033% $ 319.7k | |
| Chief Operating Officer | 3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Executive | no data | no data | no data |
5.4yrs
Average Tenure
54yo
Average Age
Experienced Management: AVXL's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.67yrs | US$1.84m | 1.47% $ 14.2m | |
| Member of the Scientific Advisory Board | 10yrs | no data | no data | |
| Member of the Scientific Advisory Board | 6yrs | no data | no data | |
| Member of the Scientific Advisory Board | 10.08yrs | no data | no data | |
| Member of the Scientific Advisory Board | 7.25yrs | no data | no data | |
| Member of the Scientific Advisory Board | 7.33yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.83yrs | US$111.32k | no data | |
| Independent Director | 8.17yrs | US$111.32k | 1.88% $ 18.2m | |
| Member of the Scientific Advisory Board | 6.83yrs | no data | no data | |
| Member of the Scientific Advisory Board | 6yrs | no data | no data | |
| Independent Director | 3yrs | US$127.32k | no data |
7.3yrs
Average Tenure
53yo
Average Age
Experienced Board: AVXL's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AVXL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.
Top Shareholders
Company Information
Anavex Life Sciences Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Anavex Life Sciences Corp.
- Ticker: AVXL
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$967.271m
- Shares outstanding: 69.49m
- Website: https://www.anavex.com
Number of Employees
Location
- Anavex Life Sciences Corp.
- 51 West 52nd Street
- 7th Floor
- New York
- New York
- 10019
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AVXL | NasdaqCM (Nasdaq Capital Market) | Yes | Common Shares | US | USD | Apr 2006 |
| 12X1 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Apr 2006 |
| 0HFR | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Apr 2006 |
Biography
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/03 23:21 |
| End of Day Share Price | 2021/03/03 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.